Sign In
Buy ELVN
$48.60
+2.64 (+5.74%)
At Close: Jun 23, 2026
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developme
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
11:00pm, Thursday, 11'th Jun 2026
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
10:39pm, Thursday, 11'th Jun 2026
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developme
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:05pm, Thursday, 11'th Jun 2026
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
08:00am, Thursday, 11'th Jun 2026
61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prio
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
04:05pm, Wednesday, 03'rd Jun 2026
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET BURLINGAME, Calif.
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
05:25pm, Monday, 01'st Jun 2026
This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sale amid strong one-year stock gains.
Enliven Therapeutics to Present at Upcoming Investor Conferences
04:05pm, Thursday, 21'st May 2026
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
04:46pm, Wednesday, 13'th May 2026
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-00
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
04:05pm, Thursday, 07'th May 2026
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
12:26pm, Saturday, 28'th Mar 2026
Helen Louise Collins exercised and sold 40,000 Common Stock shares over March 9–10, 2026, generating proceeds of ~$1.20 million at a weighted average price of $30.07 per share. The transaction reduc
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
01:59am, Sunday, 22'nd Mar 2026
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $31.76 and last traded at $30.05, with a volu
